Thirteenth biannual report of the cochrane haematological malignancies group - Focus on multiple myeloma

Journal of the National Cancer Institute

Volumn 103, Issue 17, 2011, Pages

  Bauer, Kathrin ^a   Rancea, Michaela ^a   Schmidtke, Bettina ^a   Kluge, Sabine ^a   Monsef, Ina ^a   Hübel, Kai ^a   Engert, Andreas ^a   Skoetz, Nicole ^a  

^a UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTIFIBRINOLYTIC AGENT; BLEOMYCIN; BORTEZOMIB; CLODRONIC ACID; CYCLOPHOSPHAMIDE; DACARBAZINE; DANAPAROID; DEFERASIROX; DEFEROXAMINE; DEXAMETHASONE; DOXORUBICIN; DROTRECOGIN; FLUDARABINE; HEPARIN; LENALIDOMIDE; LOW MOLECULAR WEIGHT HEPARIN; MELPHALAN; PREDNISONE; PROTEINASE INHIBITOR; RECOMBINANT BLOOD CLOTTING FACTOR 7A; RECOMBINANT HIRUDIN; RECOMBINANT THROMBOMODULIN; RECOMBINANT TISSUE FACTOR PATHWAY INHIBITOR; RITUXIMAB; THALIDOMIDE; UNINDEXED DRUG; VINBLASTINE; VINCRISTINE; ZOLEDRONIC ACID;

ACUTE LYMPHOBLASTIC LEUKEMIA; ANEMIA; ANTICOAGULANT THERAPY; ANTINEOPLASTIC ACTIVITY; ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER STAGING; CARDIOTOXICITY; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL PROTOCOL; CLINICAL RESEARCH; CONSTIPATION; DEPRESSION; DISSEMINATED INTRAVASCULAR CLOTTING; DRUG FATALITY; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ERYTHROCYTE TRANSFUSION; FATIGUE; FOLLICULAR LYMPHOMA; GERIATRIC PATIENT; HEMATOLOGIC MALIGNANCY; HODGKIN DISEASE; HUMAN; HYPOCALCEMIA; HYPOKALEMIA; INFECTION; IRON OVERLOAD; JAW OSTEONECROSIS; LEUKOPENIA; LOW DRUG DOSE; LYMPHOCYTOPENIA; MAINTENANCE THERAPY; MEDLINE; METHODOLOGY; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; MUSCLE WEAKNESS; MYELODYSPLASTIC SYNDROME; NEOPLASM; NEUROPATHY; NEUROTOXICITY; NEUTROPENIA; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SYSTEMATIC REVIEW; THROMBOCYTOPENIA; THROMBOEMBOLISM; THROMBOSIS; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; VENOUS THROMBOEMBOLISM;

EVIDENCE-BASED MEDICINE; HUMANS; MULTIPLE MYELOMA; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 80052662527     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djr271     Document Type: Article

References (30)

1. Zonder JA, Crowley J, Hussein MA, et al. Lenalidomide and high-dose dexamethasone compared with dexamethasone as initial therapy for multiple myeloma: a randomized Southwest Oncology Group trial (S0232). Blood. 2010;116(26):5838-5841.
2. Waage A, Gimsing P, Fayers P, et al.; Nordic Myeloma Study Group. Melphalan and prednisone plus thalidomide or placebo in elderly patients with multiple myeloma. Blood. 2010;116(9):1405-1412.
3. Mateos MV, Oriol A, Martinez-Lopez J, et al. Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myeloma: a randomised trial. Lancet Oncol. 2010;11(10):934-941.
4. Wijermans P, Schaafsma M, Termorshuizen F, et al.; Dutch-Belgium Cooperative Group. Phase III study of the value of thalidomide added to melphalan plus prednisone in elderly patients with newly diagnosed multiple myeloma: the HOVON 49 Study. J Clin Oncol. 2010;28(19):3160-3166.
5. Morgan GJ, Davies FE, Gregory WM, et al.; National Cancer Research Institute Haematological Oncology Clinical Study Group. First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial. Lancet. 2010;376(9757):1989-1999.
6. Engert A, Plutschow A, Eich HT, et al. Reduced treatment intensity in patients with early-stage Hodgkin's lymphoma. N Engl J Med. 2010;363(7):640-652.
7. Salles GF, Seymour JF, Offner F, et al. Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial. Lancet.;2011;377(9759):42-51.
8. Hallek M, Fischer K, Fingerle-Rowson G, et al.; German Chronic Lymphocytic Leukaemia Study Group. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet. 2010;376(9747):1164-1174.
9. Palumbo A, Anderson K. Multiple myeloma. N Engl J Med. 2011;364(11):1046-1060.
10. Harousseau JL, Dreyling M. Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2010;21(suppl 5):v155-v157.
11. Altekruse S, Kosary C, Krapcho M, et al. SEER Stat Fact Sheets: Myeloma. Bethesda, MD; 2010. http://seer.cancer.gov/statfacts/html/mulmy.html#incidence- mortality. Accessed March 5, 2011.
12. Anderson K, Alsina M, Bensinger W, et al. Multiple Myeloma. NCCN Clinical Practice Guidelines in Oncology. V.1.2011. Fort Washington, PA; 2011. http://www.nccn.org/professionals/physician-gls/PDF/myeloma.pdf. Accessed March 2, 2011.
13. Palumbo A, Sezer O, Kyle R, et al. International Myeloma Working Group guidelines for the management of multiple myeloma patients ineligible for standard high-dose chemotherapy with autologous stem cell transplantation. Leukemia. 2009;23(10):1716-1730.
14. Facon T, Mary JY, Hulin C, et al. Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial. Lancet. 2007;370(9594):1209-1218.
15. Palumbo A, Bringhen S, Caravita T, et al. Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial. Lancet. 2006;367(9513):825-831.
16. San Miguel JF, Schlag R, Khuageva NK, et al. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med. 2008;359(9):906-917.
17. Rajkumar SV, Jacobus S, Callander NS, et al. Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial. Lancet Oncol. 2010;11(1):29-37.
18. Winter MC, Holen I, Coleman RE. Exploring the anti-tumour activity of bisphosphonates in early breast cancer. Cancer Treat Rev. 2008;34(5):453-475.
19. Mhaskar R, Redzepovic J, Wheatley K, et al. Bisphosphonates in multiple myeloma. Cochrane Database Syst Rev. 2010(3):CD003188.
20. Altekruse S, Kosary C, Krapcho M, et al. National Cancer Institute. Surveillance Epidemiology and End Results (SEER) Stat Fact Sheets: Hodgkin Lymphoma. Bethesda, MD; 2010. http://seer.cancer.gov/statfacts/html/hodg.html. Accessed March 5, 2011.
21. Diehl V, Franklin J, Pfreundschuh M, et al. Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease. N Engl J Med. 2003;348(24):2386-2395.
22. Eich HT, Diehl V, Gorgen H, et al. Intensified chemotherapy and dose-reduced involved-field radiotherapy in patients with early unfavorable Hodgkin's lymphoma: final analysis of the German Hodgkin Study Group HD11 trial. J Clin Oncol. 2010;28(27):4199-4206.
23. Meerpohl JJ, Antes G, Rücker G, et al. Deferasirox for managing iron overload in people with myelodysplastic syndrome. Cochrane Database Syst Rev. 2010;(11) John Wiley & Sons, Ltd Chichester, UK. doi:101002/ 14651858CD0074612010.
24. Aul C, Giagounidis A, Germing U. Epidemiological features of myelodysplastic syndromes: results from regional cancer surveys and hospital-based statistics. Int J Hematol. 2001;73(4):405-410.
25. Balducci L. Transfusion independence in patients with myelodysplastic syndromes: impact on outcomes and quality of life. Cancer. 2006;106(10):2087- 2094.
26. Malcovati L, Porta MG, Pascutto C, et al. Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making. J Clin Oncol. 2005;23(30):7594-7603.
27. Herbst C, Rehan FA, Skoetz N, et al. Chemotherapy alone versus chemotherapy plus radiotherapy for early stage Hodgkin lymphoma. Cochrane Database Syst Rev. 2011;(2):CD0071102011. John Wiley & Sons, Ltd Chichester, UK. doi:101002/14651858CD0071102011.
28. Martí-Carvajal AJ, Cardona AF, Simancas D. Treatment for disseminated intravascular coagulation in patients with acute and chronic leukemia. Cochrane Database Syst Rev. 2010;(6):CD008562. John Wiley & Sons, Ltd Chichester, UK. doi:101002/14651858CD008562.
29. Pidala J, Djulbegovic B, Anasetti C, Kharfan-Dabaja M, Kumar A. Allogeneic hematopoietic cell transplantation for acute lymphoblastic leukemia (ALL) in first complete remission. Cochrane Database Syst Rev. 2010;(11):CD0088182010. John Wiley & Sons, Ltd Chichester, UK. doi:101002/14651858CD0088182010.
30. Franklin J, Eichenauer D, Monsef I, Engert A. Optimisation of chemotherapy and radiotherapy for untreated Hodgkin lymphoma patients with respect to second malignant neoplasms, overall and progression-free survival. Cochrane Database Syst Rev. 2010;(11):CD008814. John Wiley & Sons, Ltd Chichester, UK.